CD73: A potential biomarker for anti-PD-1 therapy

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A(2A) blockade. Since CD73 is known to be overexpressed in several human cancers and A(2A) antagonists have undergone clinical trials for Parkinson's Disease, t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Beavis, Paul A, Slaney, Clare Y, Milenkovski, Nicole, Henderson, Melissa A, Loi, Sherene, Stagg, John, Kershaw, Michael H, Darcy, Phillip K
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2015
Soggetti:
Author's View
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4589050/
https://ncbi.nlm.nih.gov/pubmed/26451321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046675
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi